Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

AIMS: To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes who are inadequately controlled with metformin (MET) monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Handelsman, Yehuda, Mathieu, Chantal, Del Prato, Stefano, Johnsson, Eva, Kurlyandskaya, Raisa, Iqbal, Nayyar, Garcia‐Sanchez, Ricardo, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667916/
https://www.ncbi.nlm.nih.gov/pubmed/30499237
http://dx.doi.org/10.1111/dom.13594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667916/
https://www.ncbi.nlm.nih.gov/pubmed/30499237
http://dx.doi.org/10.1111/dom.13594

Ejemplares similares